
Atrogi, a biotech firm based in Sweden, is entering the clinical phase with its new class of molecules for the treatment of type 2 diabetes.
The company has just received authorization to start trials in humans, the company reports in a press release.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app